PDF(Pubmed)
Abstract：
UNASSIGNED: To evaluate transperineal laser ablation (TPLA) with Echolaser® (Echolaser® TPLA, Elesta S.p.A., Calenzano, Italy) as a treatment for benign prostatic hyperplasia (BPH) and prostate cancer (PCa) using the Delphi consensus method.
UNASSIGNED: Italian and international experts on BPH and PCa participated in a collaborative consensus project. During two rounds, they expressed their opinions on Echolaser® TPLA for the treatment of BPH and PCa answering online questionnaires on indications, methodology, and potential complications of this technology. Level of agreement or disagreement to reach consensus was set at 75%. If the consensus was not achieved, questions were modified after each round. A final round was performed during an online meeting, in which results were discussed and finalized.
UNASSIGNED: Thirty-two out of forty invited experts participated and consensus was reached on all topics. Agreement was achieved on recommending Echolaser® TPLA as a treatment of BPH in patients with ample range of prostate volume, from <40 mL (80%) to >80 mL (80%), comorbidities (100%), antiplatelet or anticoagulant treatment (96%), indwelling catheter (77%), and strong will of preserving ejaculatory function (100%). Majority of respondents agreed that Echolaser® TPLA is a potential option for the treatment of localized PCa (78%) and recommended it for low-risk PCa (90%). During the final round, experts concluded that it can be used for intermediate-risk PCa and it should be proposed as an effective alternative to radical prostatectomy for patients with strong will of avoiding urinary incontinence and sexual dysfunction. Almost all participants agreed that the transperineal approach of this organ-sparing technique is safer than transrectal and transurethral approaches typical of other techniques (97% of agreement among experts). Pre-procedural assessment, technical aspects, post-procedural catheterization, pharmacological therapy, and expected outcomes were discussed, leading to statements and recommendations.
UNASSIGNED: Echolaser® TPLA is a safe and effective procedure that treats BPH and localized PCa with satisfactory functional and sexual outcomes.
UNASSIGNED: Italian and international experts on BPH and PCa participated in a collaborative consensus project. During two rounds, they expressed their opinions on Echolaser® TPLA for the treatment of BPH and PCa answering online questionnaires on indications, methodology, and potential complications of this technology. Level of agreement or disagreement to reach consensus was set at 75%. If the consensus was not achieved, questions were modified after each round. A final round was performed during an online meeting, in which results were discussed and finalized.
UNASSIGNED: Thirty-two out of forty invited experts participated and consensus was reached on all topics. Agreement was achieved on recommending Echolaser® TPLA as a treatment of BPH in patients with ample range of prostate volume, from <40 mL (80%) to >80 mL (80%), comorbidities (100%), antiplatelet or anticoagulant treatment (96%), indwelling catheter (77%), and strong will of preserving ejaculatory function (100%). Majority of respondents agreed that Echolaser® TPLA is a potential option for the treatment of localized PCa (78%) and recommended it for low-risk PCa (90%). During the final round, experts concluded that it can be used for intermediate-risk PCa and it should be proposed as an effective alternative to radical prostatectomy for patients with strong will of avoiding urinary incontinence and sexual dysfunction. Almost all participants agreed that the transperineal approach of this organ-sparing technique is safer than transrectal and transurethral approaches typical of other techniques (97% of agreement among experts). Pre-procedural assessment, technical aspects, post-procedural catheterization, pharmacological therapy, and expected outcomes were discussed, leading to statements and recommendations.
UNASSIGNED: Echolaser® TPLA is a safe and effective procedure that treats BPH and localized PCa with satisfactory functional and sexual outcomes.
摘要：
■使用Echolaser®（Echolaser®TPLA，ElestaS.p.A.,Calenzano,意大利）使用德尔菲共识方法治疗良性前列腺增生（BPH）和前列腺癌（PCa）。
■意大利和国际上的BPH和PCa专家参加了一个合作共识项目。在两轮中，他们对Echoeraser®TPLA治疗BPH和PCa发表了意见，回答了关于适应症的在线问卷，方法论，以及这项技术的潜在并发症。达成共识的协议或分歧水平定为75％。如果没有达成共识，每个回合后都会修改问题。最后一轮是在一次在线会议上进行的，其中讨论并最终确定了结果。
■40位受邀专家中有32位参加了会议，并就所有主题达成了共识。在前列腺体积较大的患者中，就推荐Echolaser®TPLA作为BPH的治疗达成了一致。从<40毫升（80％）到>80毫升（80％），合并症（100%），抗血小板或抗凝治疗（96%），留置导尿管(77%),和强烈的意志保持射精功能（100％）。大多数受访者认为Echolaser®TPLA是治疗局部PCa的潜在选择（78％），并建议将其用于低风险PCa（90％）。在最后一轮比赛中,专家得出结论，它可用于中危PCa，对于具有强烈避免尿失禁和性功能障碍的患者，应建议将其作为根治性前列腺切除术的有效替代方案。几乎所有参与者都同意，这种器官保留技术的经会阴方法比经直肠和经尿道其他技术的典型方法更安全（专家同意的97％）。程序前评估，技术方面,术后导管插入术,药物治疗,并讨论了预期结果，导致声明和建议。
■Echoeraser®TPLA是一种安全有效的方法，可治疗BPH和局部PCa，具有令人满意的功能和性结果。
■意大利和国际上的BPH和PCa专家参加了一个合作共识项目。在两轮中，他们对Echoeraser®TPLA治疗BPH和PCa发表了意见，回答了关于适应症的在线问卷，方法论，以及这项技术的潜在并发症。达成共识的协议或分歧水平定为75％。如果没有达成共识，每个回合后都会修改问题。最后一轮是在一次在线会议上进行的，其中讨论并最终确定了结果。
■40位受邀专家中有32位参加了会议，并就所有主题达成了共识。在前列腺体积较大的患者中，就推荐Echolaser®TPLA作为BPH的治疗达成了一致。从<40毫升（80％）到>80毫升（80％），合并症（100%），抗血小板或抗凝治疗（96%），留置导尿管(77%),和强烈的意志保持射精功能（100％）。大多数受访者认为Echolaser®TPLA是治疗局部PCa的潜在选择（78％），并建议将其用于低风险PCa（90％）。在最后一轮比赛中,专家得出结论，它可用于中危PCa，对于具有强烈避免尿失禁和性功能障碍的患者，应建议将其作为根治性前列腺切除术的有效替代方案。几乎所有参与者都同意，这种器官保留技术的经会阴方法比经直肠和经尿道其他技术的典型方法更安全（专家同意的97％）。程序前评估，技术方面,术后导管插入术,药物治疗,并讨论了预期结果，导致声明和建议。
■Echoeraser®TPLA是一种安全有效的方法，可治疗BPH和局部PCa，具有令人满意的功能和性结果。
